[] Scientists revealed that IL27RA is significantly upregulated in HCC. Both in vitro and in vivo experiments demonstrated that IL27RA knockdown markedly inhibited the proliferation and metastasis of HCC cells.

[Nature Cancer] The authors showed that elevated myocyte enhancer factor 2D (MEF2D)-expressing cancer precursors reprogram liver-resident macrophages, Kupffer cells, to create a growth-supportive environment.

[Pharmacological Research] The authors designed a tridomain Z-IgBD-P16, by sequentially fusing a platelet-derived growth factor receptor β (PDGFRβ)-specific affibody Z_PDGFRβ and two repeats of IgG-binding domain (IgBD) to the N-terminus of P16.

[Free Radical Biology and Medicine] Using mouse models of methionine-choline-deficiency diet-induced metabolic dysfunction-associated steatohepatitis and CCl₄-induced liver fibrosis, researchers demonstrated that macrophage-derived Delta-like ligand 4 (DLL4) exacerbates liver fibrosis by activating hepatic stellate cells.

[Stem Cell Reports] Scientists showed that activation of the canonical Wnt signaling pathway increases the reprogramming efficiency of human umbilical vein endothelial cells (HUVECs) to human induced hepatic progenitor cells by rapidly inducing chromatin remodeling and gene expression changes in the transduced HUVECs.

[European Journal of Medical Research] Investigators examined the contribution of hyaluronan-mediated motility receptor to HCC progression and its clinical implications.

[Liver International] Phase II and III clinical trials show that subcutaneous semaglutide 2.4 mg/week leads to significant improvements in hepatic steatosis, disease activity, resolution of metabolic dysfunction-associated steatohepatitis and reduction in liver fibrosis.

[Merck] Merck and Eisai announced results from the Phase III LEAP-012 trial evaluating KEYTRUDA® plus LENVIMA® in combination with transarterial chemoembolization for the treatment of patients with unresectable, non-metastatic HCC.

[Journal of Hematology & Oncology] The authors examine the engineering design, biological characteristics, and applications of chimeric antigen receptor-MSCs in oncology and immune-related disorder therapy.

[Signal Transduction and Targeted Therapy] Researchers identified the mechanosensitive cationic channel Piezo1 in bone marrow MSCs as a key suppressor of bone marrow adipogenesis by preventing local inflammation, thereby enhancing osteoblast differentiation and bone formation.

[Stem Cell Research & Therapy] MSCs have the potential to improve renal fibrosis by influencing mitochondrial dynamics and oxidative stress through the upregulation of ARMC1 expression.

[The Japan Times] A Japanese research team that includes 2025 Nobel Prize laureate Dr. Shimon Sakaguchi has developed a technique to produce regulatory T cells that suppress excessive immune activity.